Mustang Bio, Inc. (MBIO)
Largest Insider Buys in Sector
MBIO Stock Price History Chart
MBIO Stock Performance
About Mustang Bio, Inc.
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare …
Insider Activity of Mustang Bio, Inc.
Over the last 12 months, insiders at Mustang Bio, Inc. have bought $0 and sold $0 worth of Mustang Bio, Inc. stock.
On average, over the past 5 years, insiders at Mustang Bio, Inc. have bought $838,232 and sold $40,682 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,000 shares for transaction amount of $2,582 was made by Litchman Manuel MD (director) on 2022‑09‑13.
List of Insider Buy and Sell Transactions, Mustang Bio, Inc.
| 2022-09-13 | director | 5,000 0.0041% | $0.52 | $2,582 | -30.59% | |||
| 2022-09-13 | director | 5,000 0.0041% | $0.52 | $2,582 | -30.59% | |||
| 2022-03-18 | director | 5,000 0.0041% | $0.74 | $3,695 | -34.09% | |||
| 2022-03-18 | director | 4,094 0.0034% | $0.74 | $3,025 | -34.09% | |||
| 2021-12-14 | Sale | SVP, Fin. & Corp. Controller | 4,374 0.0003% | $1.83 | $8,004 | -62.80% | ||
| 2021-10-27 | President and CEO | 65,000 0.0048% | $2.24 | $145,600 | -65.88% | |||
| 2021-10-12 | Sale | SVP, Fin. & Corp. Controller | 4,450 0.0003% | $2.28 | $10,146 | -64.93% | ||
| 2021-07-30 | President and CEO | 86,206 0.0063% | $2.91 | $250,859 | -59.52% | |||
| 2021-04-09 | Sale | SVP, Fin. & Corp. Controller | 2,423 0.0002% | $3.36 | $8,141 | -22.88% | ||
| 2021-03-05 | President and CEO | 165,562 0.0135% | $3.12 | $516,553 | -12.46% | |||
| 2020-12-15 | President and CEO | 100,000 0.0114% | $2.91 | $291,000 | +2.69% | |||
| 2020-12-14 | director | 100,000 0.0115% | $2.66 | $266,000 | +12.96% | |||
| 2020-12-08 | Sale | SVP, Fin. & Corp. Controller | 5,185 0.0006% | $3.03 | $15,711 | -1.29% | ||
| 2020-10-21 | Sale | SVP, Fin. & Corp. Controller | 3,056 0.0004% | $2.97 | $9,076 | +11.39% | ||
| 2020-06-11 | President and CEO | 153,846 0.0228% | $3.25 | $500,000 | +0.15% | |||
| 2020-05-22 | Sale | President and CEO | 12,373 0.0018% | $3.04 | $37,614 | +5.84% | ||
| 2020-05-22 | Sale | SVP, Fin. & Corp. Controller | 880 0.0001% | $3.04 | $2,675 | +5.84% | ||
| 2020-05-21 | President and CEO | 90,000 0.0134% | $3.13 | $281,700 | +4.49% | |||
| 2020-05-14 | President and CEO | 90,000 0.0132% | $2.79 | $251,100 | +16.01% | |||
| 2020-03-31 | Sale | SVP, Fin. & Corp. Controller | 3,033 0.0004% | $2.64 | $8,007 | +20.90% |
Insider Historical Profitability
| Litchman Manuel MD | director | 1098987 3.0203% | $0.23 | 14 | 1 | <0.0001% |
| ROSENWALD LINDSAY A MD | director | 299181 0.8222% | $0.23 | 4 | 0 | <0.0001% |
| Achenbach Brian | SVP, Fin. & Corp. Controller | 144729 0.3977% | $0.23 | 3 | 8 | <0.0001% |
| Herskowitz Neil | director | 71000 0.1951% | $0.23 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Armistice Capital Llc | $218,400.00 | 0.6 | 210,000 | -51.81% | -$234,794.56 | <0.01 | |
| The Vanguard Group | $213,916.00 | 0.59 | 205,688 | +14.55% | +$27,171.10 | <0.0001 | |
| BlackRock | $103,067.00 | 0.28 | 99,103 | -1.34% | -$1,399.84 | <0.0001 | |
| Geode Capital Management | $50,345.00 | 0.14 | 48,397 | -2.81% | -$1,455.31 | <0.0001 | |
| Renaissance Technologies | $37,000.00 | 0.1 | 35,390 | -10.83% | -$4,495.62 | <0.0001 |